Ukuthembisa ngoNyango oLutsha lokuQala kuMhlaza weGastric/GEJ Cancer

I-Trishula Therapeutics, Inc. namhlanje ibhengeze iziphumo zokuqala ezivela kulingo oluqhubekayo lweSigaba soku-1 esivavanya i-TTX-030 ngokudityaniswa ne-budigalimab (i-anti-PD-1 yophando) kunye ne-FOLFOX yonyango lodidi lokuqala lwezigulane ezinegastric ezisezantsi/metastatic HER2 okanye umhlaza we-gastroesophageal junction. Iziphumo zophononongo zinikezelwe kwintetho yomlomo kwiNtlanganiso yoNyaka ye-American Association for Cancer Research (AACR) eNew Orleans. Idatha enikezelweyo ibonisa ukuba unyango oludibeneyo lwe-TTX-030 lwalunyamezeleke ngokubanzi kwaye lubonise iimpawu ezikhuthazayo zomsebenzi wokulwa ne-tumor.

"Amazinga okuphendula abandakanya izigulana ezine-PD-L1 ezisezantsi ezibonwe kolu hlalutyo lwangaphambili ziyakhuthaza kakhulu kwaye zixhasa amandla e-TTX-030 ukuchaphazela umgangatho wokhathalelo lwezigulana ezinomhlaza wesisu kunye ne-gastroesophageal," utshilo uZev Wainberg, MD. Unjingalwazi wezoNyango kwi-UCLA kunye no-co-director we-UCLA GI Oncology Programme. "Sijonge phambili kwiziphumo ezipheleleyo zolu lingo kunye nokuqhubela phambili kolu nyango luthembisayo."

Ukuphumelela kwangaphambili kunye neziphumo zokhuseleko zathiwa thaca njengoko kucuthwa idatha yethutyana kaMatshi 1, 2022. Zizonke izigulane ezingama-44 zabhaliswa. Izigulane ezingamashumi amabini anesithandathu (26) zazisekunyango lokufunda, kwaye ubude bexesha eliphakathi kuphononongo yayiziintsuku ezingama-214 (uluhlu lweentsuku eziyi-8-464 +). Phakathi kwezigulane ze-40 ezisebenza kakuhle, izigulane ze-21 (izigulane ze-25 ezibandakanya ukungaqinisekiswa) zifumene impendulo engcono kakhulu yempendulo epheleleyo okanye engcono kuquka i-4 CRs: ORR = 52.5% (62,5% kubandakanywa okungaqinisekisiweyo), kunye nezinga lokulawula izifo = 92.5%. Amashumi amathathu anesixhenxe (37) wezigulane ezinokuvavanya ukusebenza kakuhle zaziwazi iPD-L1 Combined Positive Score (CPS); Amazinga okuphendula kwizigulane ezine-CPS ≥1 yayiyi-65% (i-77% kuquka engaqinisekisiweyo).

Izigulane ezingamashumi amabini anesixhenxe ze-44 (61%) ziye zafumana ubuncinane isiganeko esibi (AE) salo naliphi na ibakala elithathwa njengelinxulumene ne-TTX-030 (uvavanyo lomphandi), kubandakanywa izigulane ezili-9 (20.5%) ezineBanga lesi-3/4 le-AEs. Iziganeko ezimbi zazihambelana ngokupheleleyo nezo zibonwa ngononophelo oluqhelekileyo (i-chemotherapy kunye ne-anti-PD-1).

"Idatha yethu egxininiswe kwi-AACR imele iziphumo zokuqala ezithembisayo zeklinikhi ye-anti-CD39 antibody kwizigulana ezinomhlaza wesisu kwaye iyayixhasa indima ye-TTX-030 ekubuyiseleni uthintelo lwe-adenosine-mediated immunosuppression," utshilo u-Anil Singhal, iGosa eliyiNtloko lesiGqeba. "Sijonge phambili ekuqhubeleni phambili kolu phando lwezonyango lwe-TTX-030, esikholelwa ukuba lunamandla okuphucula kakhulu i-paradigm yonyango kwizigulane ezinomhlaza."